Imaging biomarkers have emerged as indispensable tools in modern clinical medicine, offering non-invasive, quantitative, and repeatable means to assess disease onset, evolution, and response to therapy. Unlike traditional biomarkers derived from blood or tissue samples, imaging biomarkers capture spatial and temporal heterogeneity of disease processes across the entire organ or body. Their ability to provide global or regional pathophysiological information in real time makes them uniquely suited for monitoring disease progression—a critical activity that underpins therapeutic decision-making, clinical trial design, and personalized management strategies.

Defining Imaging Biomarkers: A Precision Medicine Lens

An imaging biomarker is a measurable characteristic obtained from a medical image that relates to a biological process, disease state, or therapeutic effect. These characteristics can be anatomical, functional, molecular, or hemodynamic and are derived from modalities such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and ultrasound. The term "biomarker" implies that the measurement is validated and correlates reliably with a clinical endpoint. In the context of disease progression, imaging biomarkers provide the objective, longitudinal data needed to document how a condition evolves—whether it is tumor growth, brain atrophy, arterial plaque accumulation, or joint erosion.

The rationale for using imaging biomarkers in disease monitoring is compelling. Many diseases show structural or functional alterations long before clinical symptoms become apparent. For instance, in multiple sclerosis, MRI can detect new inflammatory lesions months before the patient experiences a relapse. Similarly, in Alzheimer's disease, MRI measures of hippocampal atrophy and PET measures of amyloid deposition can be observed years before cognitive decline manifests. By capturing these early changes, imaging biomarkers enable earlier intervention, which can slow progression and improve outcomes.

The Spectrum of Imaging Modalities and Their Biomarker Roles

Magnetic Resonance Imaging (MRI)

MRI offers exquisite soft-tissue contrast and can generate both anatomical and functional biomarkers. Anatomical biomarkers include organ volume (e.g., hippocampal volume in dementia), cortical thickness, and lesion counts in multiple sclerosis. Functional biomarkers include diffusion-weighted imaging (DWI) parameters (apparent diffusion coefficient, ADC) that reflect cellular density, and perfusion-weighted imaging (PWI) parameters (cerebral blood flow, cerebral blood volume) for vascular integrity. Advanced techniques such as MR spectroscopy provide metabolic biomarkers (choline, N-acetylaspartate ratios) that indicate tumor aggressiveness or neuronal health.

Computed Tomography (CT)

CT is fast, widely available, and provides high-resolution structural information. In oncology, CT-based tumor size measurements and RECIST criteria remain the standard for assessing tumor response or progression. Coronary CT angiography can quantify coronary artery calcium scores and plaque volumes, which are biomarkers of atherosclerotic progression. CT perfusion imaging also offers biomarkers for stroke and myocardial ischemia. However, CT involves ionizing radiation, which limits its use for very frequent monitoring.

Positron Emission Tomography (PET) and Hybrid Imaging

PET provides molecular-level biomarkers by imaging the distribution of radiolabeled tracers. The most common is 18F-fluorodeoxyglucose (FDG) PET, which measures glucose metabolism—a biomarker for tumor activity and inflammation. Other tracers target specific receptors (e.g., PSMA in prostate cancer, amyloid in Alzheimer’s). Hybrid PET/CT and PET/MRI systems combine molecular and anatomical data, offering a comprehensive view of disease progression. SUV (standardized uptake value) is a quantitative biomarker used extensively in oncology and neurodegenerative disease.

Ultrasound

Ultrasound is portable, radiation-free, and provides real-time hemodynamic biomarkers. Doppler ultrasound measures blood flow velocity, resistance indices, and vessel wall thickness. Contrast-enhanced ultrasound utilizes microbubbles to produce perfusion biomarkers. In atherosclerosis, carotid intima-media thickness (IMT) is a well-validated biomarker of early vascular disease progression. Ultrasound elastography adds stiffness biomarkers for liver fibrosis and breast lesions.

Importance of Imaging Biomarkers in Monitoring Disease Progression

Monitoring disease progression is a core pillar of chronic disease management. The goal is to detect changes in disease status that necessitate adjustments in treatment, predict future outcomes, or serve as surrogate endpoints in clinical trials. Imaging biomarkers fulfill this role with several distinct advantages over clinical assessments or laboratory tests.

First, imaging biomarkers can detect subclinical progression. In oncology, a tumor may enlarge on CT before the patient feels new symptoms. In rheumatoid arthritis, MRI can identify synovitis and bone erosions before joint deformities occur. This early detection allows clinicians to escalate therapy before irreversible damage takes place.

Second, imaging biomarkers provide objective, quantifiable data that reduces the subjectivity inherent in clinical examination. For example, the Expanded Disability Status Scale (EDSS) in multiple sclerosis relies on neurological signs that can vary between examiners, whereas brain atrophy rates from MRI provide a continuous, reproducible metric of neurodegeneration.

Third, imaging biomarkers enable precise localization of disease activity. A single PET scan can reveal which metastatic lesions are metabolically active and which are quiescent, guiding targeted interventions such as radiation therapy to progressing sites while continuing observation of stable ones.

Lastly, imaging biomarkers are increasingly used as surrogate endpoints in clinical trials, accelerating drug development. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted imaging biomarkers—such as tumor shrinkage by RECIST or brain lesion load in multiple sclerosis—as primary endpoints for drug approval.

Examples of Imaging Biomarkers in Common Diseases

Oncology

Cancer is arguably the disease area where imaging biomarkers are most advanced. In lung cancer, low-dose CT screening detects early nodules and measures growth rates (volume doubling time) as a biomarker of malignancy. PET/CT with FDG tracks metabolic response to chemotherapy; a decline in SUVmax correlates with survival. In breast cancer, dynamic contrast-enhanced MRI (DCE-MRI) provides biomarkers of tumor vascular permeability (Ktrans) that predict response to anti-angiogenic agents. In brain tumors, diffusion MRI yields ADC values that differentiate true progression from pseudoprogression after radiotherapy.

Neurodegenerative Diseases

Alzheimer’s disease progression is monitored using structural MRI (hippocampal volume loss), PET with amyloid (11C-PiB) or tau tracers (18F-flortaucipir), and FDG-PET showing hypometabolism in temporoparietal regions. In Parkinson’s disease, dopamine transporter SPECT scans (DaTscan) measure loss of striatal dopamine neurons, a biomarker of motor progression. In multiple sclerosis, MRI biomarkers include new T2 lesions, contrast-enhancing lesions, and brain atrophy rate—all used to gauge disease activity and treatment efficacy.

Cardiovascular Disease

In coronary artery disease, CT coronary angiography quantifies plaque burden and composition (calcified, non-calcified) as biomarkers of progression to vulnerable plaques. Cardiac MRI measures left ventricular ejection fraction, myocardial scar burden using late gadolinium enhancement, and myocardial perfusion reserve to monitor ischemic heart disease. Carotid ultrasound IMT and plaque volume are validated biomarkers of systemic atherosclerosis progression and are used in clinical trials of lipid-lowering therapies.

Inflammatory and Musculoskeletal Diseases

Rheumatoid arthritis is monitored using MRI or ultrasound to detect synovitis, tenosynovitis, and bone erosions—biomarkers that predict joint destruction. In inflammatory bowel disease, CT and MR enterography provide biomarkers of bowel wall thickening, enhancement, and longitudinal ulceration as signs of disease activity. MRI is also used in liver fibrosis to assess elastography-based stiffness, which correlates with histological stage and predicts progression to cirrhosis.

Respiratory and Infectious Diseases

In chronic obstructive pulmonary disease (COPD), CT quantifies emphysema extent and airway wall thickness as biomarkers of disease progression. In cystic fibrosis, MRI and CT detect bronchiectasis and mucus plugging. During the COVID-19 pandemic, CT scores of lung involvement (percentage of opacity) became important biomarkers for monitoring pneumonia progression and recovery.

Advantages of Imaging Biomarkers Over Traditional Approaches

The clinical utility of imaging biomarkers stems from several unique advantages:

  • Non-invasive and safe for repeated use. Unlike biopsies, imaging can be performed serially without risk of infection or bleeding. For modalities without ionizing radiation (MRI, ultrasound), monitoring can be done as often as clinically needed. Even for CT and PET, adherence to dose-reduction protocols allows safe annual or bi-annual monitoring in at-risk populations.
  • Spatial and temporal information at macroscopic and tissue level. Imaging captures disease distribution across an entire organ or body, revealing heterogeneity that biopsy cannot. For example, a single MRI or PET scan can assess all metastatic lesions, whereas a biopsy samples only one site.
  • Detection of disease before clinical symptoms appear. This is especially valuable for diseases with long preclinical phases, such as Alzheimer’s, where intervention at early stages may be more effective.
  • Quantitative, objective and reproducible endpoints. With automated segmentation and standardized protocols, imaging biomarkers can be measured with high precision and used as surrogate endpoints in clinical trials, reducing sample size and trial duration.
  • Integration with personalized medicine. Biomarker patterns can subclassify disease (e.g., molecular subtypes of breast cancer by PET tracer uptake) and guide selection of targeted therapies.
  • Ability to monitor response and resistance. Serial imaging can distinguish responders from non-responders early in treatment, enabling treatment switches before clinical deterioration.

Current Challenges and Limitations

Despite their promise, the widespread adoption of imaging biomarkers in routine disease monitoring faces several obstacles:

Standardization and Harmonization

Imaging biomarkers are highly dependent on acquisition parameters (scanner manufacturer, field strength, pulse sequence, contrast dose and timing, reconstruction algorithms). Without standardized protocols, measurements from different sites or time points may not be comparable. Initiatives like the Quantitative Imaging Biomarkers Alliance (QIBA) and the European Imaging Biomarkers Alliance (EIBALL) are working toward setting standards, but many biomarkers still lack universally accepted thresholds for what constitutes “progression.”

Validation and Regulatory Acceptance

To be used as a clinical endpoint, an imaging biomarker must be analytically and clinically validated. This requires large, multi-site studies demonstrating that the biomarker correlates with patient outcomes and that changes reflect disease modification. For many potential biomarkers, such validation is still incomplete. Regulatory agencies require stringent evidence; only a few imaging biomarkers have qualified for use as surrogate endpoints in drug trials.

Sensitivity, Specificity, and Dynamic Range

Not all imaging biomarkers are equally sensitive to early changes. For instance, CT size measurements may not detect early tumor shrinkage that functional biomarkers like FDG-PET can. Conversely, functional changes can be confounded by inflammation, which mimics tumor progression. The dynamic range of a biomarker—the magnitude of change it can reliably detect—is critical for monitoring small changes over short intervals.

Cost and Accessibility

Advanced imaging modalities like PET/MRI or PET/CT are expensive and not universally available. Even MRI requires specialized equipment and expertise. In resource-limited settings, frequent imaging for disease monitoring may be infeasible. Cost-effectiveness analyses are needed to justify routine use of imaging biomarkers, especially for chronic diseases requiring lifelong monitoring.

Analytical Variability and Interpretation

Human interpretation of images introduces variability. Even with standardized acquisition, different radiologists may disagree on lesion counting or feature assessment. Artificial intelligence (AI) promises to reduce this variability, but AI models themselves need rigorous validation and regulation.

Future Directions: The Next Generation of Imaging Biomarkers

The field is moving rapidly toward more sophisticated, data-driven approaches to extract biomarkers from images and integrate them with other data streams.

Artificial Intelligence and Machine Learning

AI, particularly deep learning, is revolutionizing the extraction and analysis of imaging biomarkers. Convolutional neural networks can automatically segment organs, detect lesions, and compute quantitative metrics (e.g., tumor volume, bone erosion) with high reproducibility. Moreover, AI can discover new imaging biomarkers by recognizing patterns not visible to the human eye—so-called radiomics features (e.g., texture, shape, wavelet features) that correlate with genomics, treatment response, or survival. Several studies have shown that radiomics models outperform conventional biomarkers in predicting disease progression. However, AI-based biomarkers require large, well-labeled datasets and rigorous external validation to avoid overfitting and ensure generalizability.

Radiomics and Multi-Omics Integration

Radiomics involves extracting hundreds or thousands of quantitative features from images. When combined with genomic, proteomic, or metabolomic data, these features can create a multi-dimensional profile of disease progression—a field sometimes called “imaging genomics.” For example, in non-small cell lung cancer, radiomics signatures can predict EGFR mutation status and are being investigated as biomarkers for immunotherapy response. The integration of imaging biomarkers with liquid biopsy (circulating tumor DNA) promises a comprehensive monitoring approach: imaging provides spatial localization, while liquid biopsy captures molecular evolution. Such hybrid biomarkers could detect progression at earlier stages than either modality alone.

Novel Tracers and Molecular Targets

In PET imaging, new tracers are being developed to target immune cells (F18-AraG for T-cell activation, F18-FEDAC for macrophages), enabling imaging tumor–immune interactions that underlie immunotherapy response. Similarly, in MRI, hyperpolarized 13C-pyruvate imaging provides real-time biomarkers for metabolic flux (lactate production) that can detect early treatment response in prostate cancer. Ultrasound-targeted microbubble imaging is being explored as a way to deliver therapeutics and simultaneously monitor delivery with molecular imaging biomarkers. These developments will expand the repertoire of biomarkers available for monitoring progression in specific therapeutic contexts.

Standardization and Open Data Initiatives

Efforts like the Medical Image Computing and Computer-Assisted Intervention (MICCAI) challenge datasets, The Cancer Imaging Archive (TCIA), and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) provide publicly available data with standard imaging protocols. Such resources accelerate biomarker discovery and validation. International consortia are working toward common data standards (DICOM and appropriate use criteria) to ensure that imaging biomarkers can be pooled across sites. The development of reference standards for normal values (e.g., age- and sex-specific brain volumes) will further enhance the clinical utility of biomarkers for disease monitoring.

Point-of-Care and Portable Imaging

Advances in portable ultrasound and low-field MRI (e.g., hyperpolarized gas MRI for lung imaging) are making imaging biomarkers more accessible for point-of-care monitoring. AI-based interpretation can be deployed on mobile devices, allowing disease progression to be tracked in outpatient settings or even at home. This democratization of imaging biomarkers will be crucial for chronic diseases like heart failure or COPD, where frequent monitoring can prevent hospitalization.

Practical Considerations for Clinicians and Researchers

For clinicians looking to incorporate imaging biomarkers into disease monitoring, several practical steps are important:

  • Choose biomarkers with proven clinical validity for the specific disease and disease stage. For example, hippocampal volume is validated for Alzheimer’s but not for Mild Cognitive Impairment in non-standardized settings.
  • Use standardized imaging protocols and preferably the same scanner vendor and software for longitudinal comparisons.
  • Leverage quantitative reading tools that provide automated segmentation and trend analysis rather than relying solely on visual assessment.
  • Consider the “biological noise” in the biomarker—e.g., hydration status affects liver stiffness, menstrual cycle affects breast density.
  • Interpret imaging biomarkers in conjunction with clinical and laboratory data; no single biomarker tells the whole story.

For researchers, the path forward requires rigorous validation of new biomarkers against hard clinical endpoints (survival, organ failure, disability). Collaboration across specialties—radiology, pathology, bioinformatics, clinical medicine—is essential. Funding agencies are increasingly prioritizing quantitative imaging research, as evidenced by initiatives from the National Institutes of Health (NIH) and the Radiological Society of North America (RSNA). The integration of imaging biomarkers into electronic health records and decision-support systems will enable real-time monitoring and trigger appropriate interventions.

Conclusion

Imaging biomarkers have transformed the landscape of disease monitoring, offering objective, non-invasive, and spatially informative tools that capture the dynamics of disease progression. From early detection in asymptomatic individuals to guiding therapy switches in advanced disease, these biomarkers enhance clinical precision and support the goals of personalized medicine. While challenges of standardization, validation, and cost remain, ongoing advances in AI, radiomics, molecular imaging, and portable technology promise to overcome these barriers. As the evidence base grows and regulatory acceptance widens, imaging biomarkers will become increasingly integral to standard clinical practice—providing every patient with a tailored, data-driven view of their disease trajectory.